GW&K Investment Management LLC Increases Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

GW&K Investment Management LLC lifted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 18.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 2,123,488 shares of the medical device company’s stock after acquiring an additional 323,674 shares during the period. GW&K Investment Management LLC’s holdings in Tandem Diabetes Care were worth $76,488,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Brooklyn Investment Group purchased a new stake in Tandem Diabetes Care in the 3rd quarter worth about $28,000. Assetmark Inc. bought a new position in shares of Tandem Diabetes Care during the third quarter valued at approximately $29,000. McIlrath & Eck LLC purchased a new stake in shares of Tandem Diabetes Care in the third quarter worth approximately $52,000. Venturi Wealth Management LLC lifted its stake in shares of Tandem Diabetes Care by 5,955.9% during the 4th quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company’s stock worth $74,000 after acquiring an additional 2,025 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Tandem Diabetes Care during the 3rd quarter valued at $105,000.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TNDM. Robert W. Baird reduced their target price on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a research note on Thursday. Sanford C. Bernstein assumed coverage on shares of Tandem Diabetes Care in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price target on the stock. Royal Bank of Canada lowered their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price on the stock in a research note on Monday, December 2nd. Finally, Barclays lifted their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.38.

Tandem Diabetes Care Trading Down 35.2 %

TNDM opened at $21.75 on Friday. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -11.27 and a beta of 1.32. Tandem Diabetes Care, Inc. has a 12 month low of $21.43 and a 12 month high of $53.69. The stock has a fifty day moving average price of $35.45 and a 200-day moving average price of $36.62.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.